JGO Weekly Summary (April 29, 2025)

This episode features an in-depth discussion of the Asian cohort analysis from the AtTEnd/ENGOT-EN7 phase III trial, which evaluated atezolizumab in combination with carboplatin and paclitaxel for advanced or recurrent endometrial carcinoma. While atezolizumab improved progression-free survival in mismatch repair-deficient tumors across both Asian and non-Asian populations, it showed no benefit—and potential harm—in mismatch repair-proficient Asian patients. The analysis also revealed a higher incidence of severe adverse events among Asians receiving atezolizumab. These findings highlight the importance of considering ethnic differences in treatment response and toxicity in future clinical trials.